281 related articles for article (PubMed ID: 28284173)
1. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Stacchiotti S; Tortoreto M; Bozzi F; Tamborini E; Morosi C; Messina A; Libertini M; Palassini E; Cominetti D; Negri T; Gronchi A; Pilotti S; Zaffaroni N; Casali PG
Clin Cancer Res; 2013 Sep; 19(18):5192-201. PubMed ID: 23888069
[TBL] [Abstract][Full Text] [Related]
3. Response to chemotherapy of solitary fibrous tumour: a retrospective study.
Stacchiotti S; Libertini M; Negri T; Palassini E; Gronchi A; Fatigoni S; Poletti P; Vincenzi B; Dei Tos AP; Mariani L; Pilotti S; Casali PG
Eur J Cancer; 2013 Jul; 49(10):2376-83. PubMed ID: 23566418
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.
Khalifa J; Ouali M; Chaltiel L; Le Guellec S; Le Cesne A; Blay JY; Cousin P; Chaigneau L; Bompas E; Piperno-Neumann S; Bui-Nguyen B; Rios M; Delord JP; Penel N; Chevreau C
BMC Cancer; 2015 Oct; 15():700. PubMed ID: 26472661
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
6. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
7. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.
Stacchiotti S; Simeone N; Lo Vullo S; Morosi C; Greco FG; Gronchi A; Barisella M; Collini P; Zaffaroni N; Dagrada GP; Frezza AM; Mariani L; Casali PG
Eur J Cancer; 2019 Jan; 106():225-233. PubMed ID: 30528807
[TBL] [Abstract][Full Text] [Related]
8. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK
Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712
[TBL] [Abstract][Full Text] [Related]
10. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
11. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
13. Systemic management strategies for metastatic soft tissue sarcoma.
Movva S; Verschraegen C
Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Grignani G; Martín-Broto J; Schuler M; Reichardt P
Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
16. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of advanced soft-tissue sarcomas.
Antman KH; Elias AD
Semin Surg Oncol; 1988; 4(1):53-8. PubMed ID: 3281212
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
20. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
